20/20 GeneSystems, Inc. offering is now closed and is no longer accepting investments.

INVEST IN 20/20 GENESYSTEMS, INC. TODAY!

Lab-Based Diagnostic Testing Powered by AI and Real-World Data

20/20 GeneSystems develops and commercializes clinical laboratory tests that are improved with machine learning and real-world data. Through our high-complexity CLIA lab, we offer what is believed to be the first multi-cancer screening blood test in the U.S. costing under $200. In response to the global pandemic, we expanded our CLIA laboratory test menu to include PCR testing. Due to our ability to scale our COVID testing operation, 2021 revenues exceeded $9 million with over $1 million in net profits for the year. This represents a more than 300% increase over 2020 revenues. As a result, we ranked no. 131 on the Inc. 5000 list of America’s fastest-growing companies in 2022. To grow our portfolio of tests, the Company has built a Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first accelerator facility for diagnostics start-ups. Our CLIAx is expected to help fuel our product and revenue growth for the next five years and already has two companies signed up to join.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
20/20 GeneSystems, Inc.

$232,186.66 Raised

Reasons to Invest


  • One of the first in a fast growing market: 20/20 GeneSystems is one of the first organizations in the white-hot market for multi-cancer early detection (MCED) screening blood tests and is collecting test outcome data from around the world to help us refine and improve our algorithms and remain a market leader. Since the start of 2022 advancing MCEDs has become a priority for  members of Congress and the  U.S. National Cancer Institute.


  • Experienced Team: Our CEO previously established strategic partnerships with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics and Smiths Detection.  Our Board members have built and sold several successful diagnostics and medtech companies. 


  • Investor backing: Our shareholders include China’s Ping An Ventures, likely the world’s largest Healthcare AI company (300 million users of its mobile diagnostic app) & thousands of investors, as well as the Keiretsu Forum, family offices, and over 8,000 crowd investors.

overview


Lab Testing Made Smarter


20/20 GeneSystems, Inc. is one of the fastest growing privately-owned companies in the nation. Steadfastly committed since its inception to developing a leading position in the cancer screening market, 20/20 GeneSystems successfully leveraged its clinical laboratory operational skills and technical expertise to expand its viral testing services to meet the needs of the community during the COVID-19 pandemic.


Learn More: Yahoo! Finance




We believe OneTest is one of the first tests of its kind to combine the results of six cancer biomarker tests (from a single blood draw) and personal health data with an artificial intelligence algorithm to calculate a probability score for many different types of cancers.


The Problem


We Usually Don't Catch Cancer Early Enough


Cancer is the 2nd leading cause of death in most of the industrialized world with survival rates closely tied to stage at time of diagnosis. For example, the 5-year survival rate for lung cancer falls 90% when it passes from Stage 1 to Stage 4.


We believe 20/20 GeneSystems is positioned to help transform the way cancer is screened worldwide, and in doing so, help score a major victory in the fight against this dreaded disease. Despite advancements in treatment, once cancer has gone undetected through its early stages, it frequently becomes lethal. Therefore, the key to winning the fight against cancer is transforming the way cancer is screened for and detected.   

The Solution


20/20 GeneSystems' OneTest: A Machine Learning Enhanced Blood Test to Help Detect Multiple Cancers Early


20/20 GeneSystems develops and commercializes clinical laboratory tests that are improved with machine learning and real-world data. Through our high-complexity CLIA lab we offer what is believed to be one of the first multi-cancer screening blood tests in the U.S. costing under $200. In response to the global pandemic, we expanded our CLIA laboratory test menu to include PCR testing. This expansion allowed us to scale our COVID testing operation and as a result our 2021 revenues to $9,622,332 increasing revenues from 2020 by $7,291,804 and net income for 2021 is $2,071,777. 


Learn More: Yahoo! Finance



OneTest™ aids in the early detection of multiple cancers from one blood sample. See www.OneTest.AI. Individuals can easily order the test on our website and then visit a nearby retail clinic for blood sample collection. The blood samples are forwarded to our CLIA lab where they are analyzed for the levels of a panel of tumor antigens. These levels are then compared with the consumers' prior test results as well as those of over 200,000 individuals with known cancer outcomes that have had these biomarkers tested previously. A machine learning algorithm then predicts the likelihood of having cancer. Doctors’ familiar with the workings of this test are available to consult via telemedicine.



*This video includes computer generated images to simulate the one test process.


Key features of the current product are as follows:

  • A cloud accessible tool to improve the accuracy of tumor marker blood tests (CEA, AFP, CA-19.9, etc.)

  • Useful in early detection of multiple types of cancer (lung, liver, pancreas, etc.)

  • Incorporates clinical factors (age, gender, smoking history, etc.)

  • Stores & displays each individual’s biomarker trends from successive tests

  • Uses machine learning / AI

To the best of our knowledge, 20/20 GeneSystems is one of the first companies to commercialize multi-cancer screening blood tests powered by AI and machine learning algorithms built with real-world outcome data from tens of thousands of previously tested individuals. Screening tests and algorithms must be validated in a “pre-diagnostic” population (i.e. individuals tested before being diagnosed with cancer) to be proven reliable. Our approach of “harvesting” real-world data permits rapid validation from this population with limited costs.

We sell OneTest (www.OneTest.AI) to both individuals and occupational groups (e.g. Fire Departments) with proven high cancer risk.

our traction


Growing Year-Over-Year 


This represents an increase of more than 300% increase over 2020 revenues and more than 3,000% increase over 2019 revenues ($288,300). With our ability to enhance our operations with COVID testing, we ranked no.  on the Inc. 5000 list of America’s fastest growing companies in 2021 and expect to rank in the top 200 on this year’s list. 



Key goals and priorities to help yield sustained commercial traction and revenue growth in the 24 month period following the pandemic emergency include the following:


  • Significantly Grow OneTest for Cancer in the USA. Expanding the number of retail clinics that draw blood for OneTest from 125 to 500 would permit faster scale of this product .  
  • Develop OneTest for Heart Health. We have several partnerships underway with both commercial entities and researchers about a panel of blood based cardiac markers that can be combined with data from wearables such as blood pressure and EKG and use machine learning algorithms that can help predict the likelihood of cardiac arrest and stroke.
  • New Tests for Wellness, Prevention, and Early Detection. We are signing up  market ready diagnostic companies into the Clinical Laboratory Innovation AxceleratorTM; One partner from Australia has begun to set their operation on site and others are in discussion.  These partnerships will provide for co-marketing arrangements along with royalty and service fees in exchange for operating in the accelerator.  

The Market


Multi-Cancer Screening Blood Tests are for Everyone


Recent studies by leading cancer geneticists at Johns Hopkins suggest that far more cancers are caused by aging than from family history, the environment, or lifestyle. This suggests that all adults, beginning in middle age, should be screened regularly for a wide array of cancers. In fact, throughout East Asia most adults receive tumor antigens testing each year at “Health Check Centers.”

Thus, the market for multi-cancer screening blood tests includes all adults roughly between the ages of 45 and 75 (the optimum ages for cancer screening). According to our research, there are no widely used safe and affordable tests that help identify as many cancers as our OneTest at comparable price and accuracy levels.

While we see OneTest being a universal test in the long-term, in the near-term we are focusing on occupations with proven high incidents of lethal cancers. Studies by the U.S. National Institute of Occupational Safety & Health (NIOSH) demonstrate that firefighters are one such occupation. Thus, America’s more than one million career and volunteer firefighters are a key market for OneTest. See www.OneTestforCancer.com/firefighters.



why invest


Invest in Saving Lives


20/20 GeneSystems is pioneering a brand new approach to improve the accuracy and usefulness of conventional clinical lab testing. Rather than simply reporting the biomarker levels, in the way they have for decades, we leverage vast amounts of real-world data together with machine learning to compare the individual’s test results to those of tens of thousands of others with known health outcomes. This proprietary technique is already being used to improve early cancer detection and will soon be deployed to help flag risks of heart attacks and other serious diseases. 



Our strategy is to continue to expand our portfolio of tests, to do this the company has built what it believes is the country’s first Accelerator facility for diagnostics start-ups worldwide. Our Clinical Laboratory Innovation Axcelerator™ is expected to help fuel 20/20 GeneSystem’s product offerings and in turn overall revenue growth into the future.

CLIAx: bringing cutting edge lab tests to market


In 2022, we launched CLIAx, what may be the United State’s first accelerator facility for diagnostics start-ups meant to bring in the best cutting-edge lab tests from around the world into the US market and 20/20’s product pipeline. CLIAx offers a “soft landing” to testing innovators from around the world and provides sales support for products and services that address the markets of Early Detection, Personalized Medicine and Wellness and Prevention. On the 2nd of June 2022, CLIAx held a launch ceremony which included Montgomery County Maryland Executive Marc Elrich,  Montgomery County Maryland Council President Gabe Albornoz and Maryland State Delegate Lily Qi. We already have two companies sign up for CLIAx with more expected to follow in H2 2022.


Join us!


Learn More: Yahoo! Finance

ABOUT

HEADQUARTERS

15810 Gaither Road, Suite 235
Gaithersburg, MD 20877
VALUATION

$59.91M
PREVIOUSLY CROWDFUNDED

$10M

20/20 GeneSystems develops and commercializes clinical laboratory tests that are improved with machine learning and real-world data. Through our high-complexity CLIA lab, we offer what is believed to be the first multi-cancer screening blood test in the U.S. costing under $200. In response to the global pandemic, we expanded our CLIA laboratory test menu to include PCR testing. Due to our ability to scale our COVID testing operation, 2021 revenues exceeded $9 million with over $1 million in net profits for the year. This represents a more than 300% increase over 2020 revenues. As a result, we ranked no. 131 on the Inc. 5000 list of America’s fastest-growing companies in 2022. To grow our portfolio of tests, the Company has built a Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first accelerator facility for diagnostics start-ups. Our CLIAx is expected to help fuel our product and revenue growth for the next five years and already has two companies signed up to join.

TEAM

Jonathan Cohen

Jonathan Cohen

Chief Executive Officer, President and Director

Mr. Cohen is the founder of our company and has served as Chief Executive Officer, President, and a Director since its inception. He is a co-inventor of two of our most successful products, OneTest and BioCheck, and has led the commercial launch and sales of both. He has also spearheaded license, research, technology transfer, investment, and sales and marketing agreements with Fortune 500 companies such as Eastman Kodak, Abbott Diagnostics, Johnson & Johnson, IBM, and Ping An, the largest health insurance company in China. Mr. Cohen has also been a leading advocate in Annapolis, MD and on Capitol Hill on behalf of small and emerging biotechnology companies. Before founding our company, Mr. Cohen was patent and general counsel for two publicly traded companies, Ventana Medical Systems Inc. (acquired by Roche diagnostics in 2008), from 1999 to 2000, and Oncor Inc., from 1997 to 1999. Mr. Cohen is a registered patent attorney with more than 18 years of experience in biotechnology patents and licensing matters. Mr. Cohen has a Master of Science Degree in Biotechnology from Johns Hopkins University and a law degree from the American University

Jiming Zhou

Jiming Zhou

Chief Operating Officer

Dr. Zhou graduated from sichuan university (china) and served as an associate professor before moving to the U.S., conducting 7 years of academic research at the university of Iowa. Dr. Zhou published 30+ peer-reviewed research papers, awarded multiple grants and patents. In 2005, Dr. Zhou then joined industrial R&D, and led a joint pharmaceutical project with total milestones of $330 million. From 2009, Dr. Zhou managed multiple clinical labs and co-funded 2 companies, worked with many large U.S. and Chinese public and private healthcare institutes in multiple projects.

Michael Lebowitz

Michael Lebowitz

Chief Scientific Officer

Dr. Lebowitz has more than 18 years of experience in biomedical research within the biotech industry having previously served as vice president of research at Ariadne Diagnostics, LLC. He has been directly involved in the commercial launch of six cancer diagnostic tests and the research leading up to a pharmaceutical IND approval. Dr. Lebowitz holds a Ph.D. from the Johns Hopkins University School of Medicine in biochemistry, cellular, and molecular biology where he subsequently completed a three-year fellowship in immunology in the department of pathology, division of immunopathology.

Amy Colton

Amy Colton

Senior Sales

Amy Colton joined our team as a senior sales representative, focused on the business development and expansion of OneTest sales. Prior to joining us, she has spent her career in marketing and branding, as well as launching flagship brands for companies like Merck and Allergan, as well as several startup diagnostics companies. Ms. Colton graduated with a BFA in graphic design as well as a BFA in art history from the Savannah College of Art and Design.

Ron Baker

Ron Baker

Sales Director

Mr. Baker's responsibilities include identifying new business opportunities that will expand our menu of testing and services. He has held senior-level positions in management, operations, and technical and business development with Roche Diagnostics, Corning Life Sciences, Bio Reliance Corporation, International Clinical Labs, and SGS Life Sciences (Belgium). He also helped launch and build Molecular Oncology, Inc., a specialized oncology testing services company.  

Alexis Levy

Alexis Levy

Senior Sales Representative

Alexis Levy is a senior sales representative focused on the development and expansion of OneTest sales. Prior to being named senior sales representative, she was sales manager at Alpha Biosciences, where she oversaw the entirety of the company’s worldwide sales. Ms. Levy brings with her over 13 years of experience navigating both the biotech and sales industries. She attended Sweet Briar College where she earned a BS in biology.

 

Anne Shiflett

Anne Shiflett

Director of Finance

Anne Shiflett brings over 30 years of managerial, financial, and accounting experience to our team. With her extensive life science experience in leading the financial management aspects of companies in diagnostics, drug development to contract research, and contract development manufacturing organizations, she brings critical perspectives as a partner on the executive management team.

John Compton

John Compton

Chairman of the Board of Directors

Mr. Compton has served as Chairman of the Board since July 2016. He has over 30 years of experience in the development and application of molecular biological techniques to answer questions about genetics and epidermal differentiation, and has authored more than 80 publications in the field. Mr. Compton served as Vice-President of BioReference Laboratories from 2007 to 2013. Previously, Mr. Compton was founder, and served as Scientific Director and Co-President of GeneDx Inc, from 2000 to 2006, the assets of which were acquired by BioReference Laboratories (now part of Opko) in September 2006. Mr. Compton also serves as Mayor of the Town of Washington Grove, MD (2000-2008, 2018-present), on the Board of Directors of Quertle Inc, Henderson NV (text search software and data analytics), and chairs the Boards of the non-profit BlackRock Center for the Arts, Germantown MD (education and performing arts center) and the Pinkney Center for Science and Technology at Montgomery College Germantown Campus. Mr. Compton holds B.S. degrees in Physics and Biology from MIT, received his Ph.D. from the University of California, Berkeley, in Biophysics, and was a Staff Scientist at the NIAMS, National Institutes of Health, Bethesda, from 1991-2000. In 2003, he was awarded the Entrepreneur of the Year award by the Technology Council of Maryland.

Richard M. Cohen

Richard M. Cohen

Director

Mr. Cohen has served as a member of our board of directors since July 2016. He is an experienced CEO/CFO at public and private companies. His professional experience includes biotech, financial services and diversified media and he maintains excellent contacts with capital financing sources on and off Wall Street. He has been the President of Richard M Cohen Consultants since 1995, a company providing financial consulting services to both public and private companies. From March 2012 to July 2015, he was the Founder and Managing Partner of Chord Advisors, a firm providing outsourced CFO services to both public and private companies. He was the CEO and CFO of CorMedix Inc., Bridgewater, NJ, a publicly traded medical device/biotechnology company with an intrapericardial therapy product targeted to markets in the U.S. and Europe, from 2010 to 2013. He has served on the board of directors and audit committees of Smart for Life, Inc. (2022 to present), Ondas Holdings Inc. (2018 to present), Helix BioMedix, Inc. (2006 to present), CorMedix Inc. (2010 to 2013), and Rodman & Renshaw (2008 to 2012). Mr. Cohen’s academic credentials include an MBA from Stanford University and B.S. with honors from Wharton School, University of Pennsylvania. Mr. Cohen has no relation to Jonathan Cohen.

John W. Rollins

John W. Rollins

Director

Mr. Rollins has served as a member of our board of directors since November 2017. He has served on multiple boards and chairs the board of directors of the MedStar Southern Maryland Hospital Center (2014 to present). From 2001 to 2010, he taught Entrepreneurship at the George Washington University School of Business and founded the GW New Venture Competition and served as its Director from 2007 to 2014. In 2003, Mr. Rollins founded StreamCenter, Inc., a firm that pioneered online education using video streaming, and served as chair of the board of directors from 2003 to 2008, and CEO from 2008 to 2010. Prior to 2001, he founded and served for three decades as the CEO and chairman of AZTECH Software Corporation (Bethesda, MD), the nation’s first specialized provider of information technology services to non-profit organizations. Mr. Rollins’s board experience has included serving as Trustee of the National Park Trust (Vice Chair and Treasurer) (1990 to present), Director of the MedStar Georgetown University Hospital (Vice Chair) (2002 to 2013), the Washington Hospital Center (Vice Chair and Treasurer) (1977 to 2002), and the U.S. Association for Small Business & Entrepreneurship (2004 to 2006). Mr. Rollins earned his A.B. in Mathematics from Dartmouth and his M.B.A. in Finance from the Stanford University Graduate School of Business.

Michael A. Ross

Michael A. Ross

Director

Dr. Ross has served as a member of our board of directors since July 2016. He has served as the Chairman and CEO of Euclid Systems Corporation (Herndon, VA) since 2015, where he led the growth of this ophthalmic medical device company from $3.1 million to over $20 Million in five years. The bulk of Euclid’s sales are in China and East Asia where Dr. Ross visits 4-5 times per year. Prior to joining Euclid, he was CEO of E-P Therapeutics from 2010 to 2012, and was a Medical and Scientific Advisor to StemCyte, Inc. 2009 to 2010. He is Board-certified in Obstetrics and Gynecology and is a founding member of an OB-GYN-Infertility practice in Northern Virginia from 1980 to 2007. Dr. Ross has been a Clinical Professor of Obstetrics and Gynecology, George Washington University Medical Center since 1979, and has served on the Boards of Directors of several biotech and medical device companies. He has a B.S. in Chemistry and Biology from Dickinson College and an M.D. from George Washington University.

Ming Li

Ming Li

Director

Li Ming is the general manager of Ping An Ventures with 10+ years of experience in private equity investment. In Ping An Ventures, he covers investment opportunities in biotech, medical equipment, medical services and TMT.

Investment cases include Cloudr Group (9955.HK), General Healthy (605186.SH), HuaTong (605196.SH), BEKE.US.

Before joining Ping An Ventures, Li Ming was the executive director in Ping An Bright Fortune Capital, and investment director in Fosun Capital covering medical service and TMT investment business.

Li Ming holds an MBA degree from Cheung Kong Graduate School of Business.

Li Ming was the Executive Director of Ping An Ventures in the past 3 years.

TERMS

20/20 GeneSystems, Inc.
Overview
INTEREST RATE
6.0%
MATURITY DATE
Feb 28, 2025
VALUATION CAP
$58.4M
AMOUNT RAISED
$232,186.66
Breakdown
MIN INVESTMENT
$500.00
DISCOUNT RATE
10.0%
CONVERSION TRIGGER
$100,000.00
OFFERING TYPE
Convertible Notes
TYPE OF EQUITY
Non-Voting Common Stock


Company

:

20/20 GeneSystems, Inc.

Corporate Address

:

15810 Gaither Road, Suite 235, Gaithersburg, MD 20877

Offering Minimum

:

$9,995.40

Offering Maximum

:

$4,999,995.00

Minimum Investment Amount

(per investor)

:

$500.00











Terms


Offering Type

:

Convertible Promissory Notes

Type of Equity Converted Into

:

Common Stock

Conversion Trigger

:

$100,000.00

Maturity Date

:

February 28, 2025

Valuation Cap

:

$58,400,000.00

Discount Rate

:

10.0%

Annual Interest Rate

:

6.0%
















What is a Convertible Note?

A convertible note offers you the right to receive Common Stock in 20/20 GeneSystems, Inc.. The amount of Common Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $100,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $58,400,000.00  Valuation Cap or if less, then you will receive a 10.0% discount on the price the new investors are paying.  You also receive 6.0% interest per year added to your investment.  When the maturity date is reached, if the note has not converted then you are entitled to receive Common Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).



Investment Incentives and Bonuses*

Time-Based:

Invest within the first 2 weeks and receive a 25% increase in the annual interest rate on Convertible Promissory Notes in this Offering, where by the interest rate will increase from 6% to 7.5%.

Amount-Based:

Tier 1 | $500+

Receive 1/3 off all 20/20 lab tests for 12 months. (Only if available in your country)

Tier 2 | $1,000+

Receive 1/2 off all 20/20 lab tests for 12 months. (Only if available in your country)

Tier 3 | $2,500+

Receive 1/2 off all 20/20 lab tests for 18 months. (Only if available in your country)

Tier 4 | $5,000+

Receive 1/2 off all 20/20 lab tests for 24 months. (Only if available in your country)

Tier 5 | $10,000+

Receive 1/2 off all 20/20 lab tests for life. (Only if available in your country)

*All perks occur when the offering is completed.

Audience-Based Perk

Loyalty Bonus | 50% bonus on interest

Previous 20/20 GeneSystems investors are eligible for an additional bonus on interest.

The 10% StartEngine Owners' Bonus

20/20 GeneSystems, Inc. will offer a 10% additional bonus for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

Eligible StartEngine shareholders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 6.6% instead of 6%.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the Company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the Offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.

ALL UPDATES

12.14.22

Only 2 days left to invest in 20/20 Gene Systems!

Join us as we help bend the curve of cancer mortality in the U.S. through earlier detection.  Our campaign ends on 12/15/2022 at 11:59:59PM PST. 

12.12.22

20/20 Gene Systems, Inc. Start Engine Campaign ends in less than 3 days!

At this time, 20/20 Gene Systems has decided to end its current financial raise.  The Campaign ends at 11:59:59PM PST on 12/15/2022.  We thank all those that invested since the beginning of this campaign, 8/15/2022 and encourage those that have not yet invested, to do so within the next week.  If you want to stay up date on our progress, visit our website at www.2020gene.com.  Keep an eye out for our Quarterly Newsletter and if you have not already done so, view our recent 20/20 Informational Webinar at the Webinar Link.

11.29.22

Making Cancer Testing More Convenient

Last week we participated in HLTH 2022, a very exciting healthcare conference in Las Vegas attended by over 10,000 companies, entrepreneurs, investors, and medical providers.   While there we met with leaders from several large retailers and pharmacy chains as well as companies that have developed new devices to collect capillary blood to avoid the need for traditional, often painful venous blood draws.  

 

20/20’s vision is that for cancer screening to be impactful it must be both affordable, convenient and easily accessible.   One tool to advance that goal is to make our OneTest for Cancer and our other products available at local pharmacies using fingerstick collected blood (typically pharmacies to not employ phlebotomists that draw blood from the arm).  Next month we are initiating a study comparing the equivalency of capillary collected blood with venous blood for the tumor antigens that are measured in our test.   To the best of our knowledge these equivalencies have not yet been established by others.

 

We expect to have more to report on these exciting efforts to make OneTest available at national pharmacy chains during the first Quarter of the new year.

11.23.22

20/20 Informational Webinar available for your Review

If you missed the live Webinar on November 17, 2022 at 12PM EST, the link to review at your convenience is noted below: 


Webinar Link

https://us02web.zoom.us/rec/share/ecRcpD444ESaxEyZ1Y8gxzRZS2kIbm2sBWH5u_WU2juH-n8sKKlMprUWjnzikx2d.Yan18RIBqx5mEXGn?startTime=1668704369000

Passcode: Yr46gb#D

11.14.22

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the 20/20 GeneSystems, Inc. offering. Here's an excerpt describing the specifics of the change:


Issuer is extending campaign end date


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

11.10.22

One Week Until the 20/20 Investor Webinar - REGISTER NOW

Join Jonathan Cohen, CEO for an Investor Webinar on Nov 17, 2022 12:00 PM Eastern Time. This will give you a chance to ask questions and learn more about the Company. 

 

We look forward to you joining us for this Webinar. 

 

Register in advance for this meeting:

https://us02web.zoom.us/meeting/register/tZMtdeGurzosHtb0J40d0AqrWQazd2M9tJr3 



After registering, you will receive a confirmation email containing information about joining the meeting.

11.07.22

Join Our Investor Webinar on November 17, 2022 12:00PM EST

Join Jonathan Cohen, CEO for an Investor Webinar on Nov 17, 2022 12:00 PM Eastern Time.  This will give you a chance to ask questions and learn more about the Company. 

We look forward to you joining us for this Webinar. 

Register in advance for this meeting:

https://us02web.zoom.us/meeting/register/tZMtdeGurzosHtb0J40d0AqrWQazd2M9tJr3 

After registering, you will receive a confirmation email containing information about joining the meeting.

11.01.22

California, Here We Come!


20/20's high complexity clinical laboratory, currently regulated under CLIA and the State of Maryland, just received accreditation from the College of American Pathologists. CAP Accreditation is a pre-requisite for a license from the California Department of Public Health to receive and process specimens from California residents, which was also received last month. We estimate that about 20% of consumers interested in our tests reside in that state.

10.19.22

Wall Street Journal covers the new and growing market of MCEDs

Last week the Wall Street Journal had a feature story on the momentum of multi-cancer early detection (MCED) blood tests.   The story can be downloaded here. We believe that 20/20, along with Grail, are among the first entrants into a market that will grow to $50 billion in yearly sales according to the analyst cited in the article. Our approach of measuring tumor antigens—rather than DNA biomarkers—permits far less expensive tests ($189 vs. $949) without demonstrated loss of accuracy.

10.18.22

20/20 Runs Full Page Ad in Prevention Magazine

We’ve achieved another major milestone in our integrated campaign with Prevention magazine. During the week of October 10th, hundreds of thousands of subscribers of Prevention and newsstands began to receive the November issue of the magazine, which features our one-page, informative, advertisement for OneTest for Cancer. This piece of credible marketing collateral significantly extends the reach of visibility for OneTest for Cancer and increases the opportunity for the health-conscious consumer to engage with our brand. These touchpoints of the campaign could not come at a more opportune time as we’ve begun to see greater awareness and understanding for MCEDs and are enthusiastic about the continued momentum this will drive.

 

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into 20/20 GeneSystems, Inc..

$500.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$500.00

Tier 1

Receive 1/3 off all 20/20 lab tests for 12 months. (Only if available in your country)

$1,000.00

Tier 2

Receive 1/2 off all 20/20 lab tests for 12 months. (Only if available in your country)

$2,500.00

Tier 3

Receive 1/2 off all 20/20 lab tests for 18 months. (Only if available in your country)

$5,000.00

Tier 4

Receive 1/2 off all 20/20 lab tests for 24 months. (Only if available in your country)

$10,000.00

Tier 5

Receive 1/2 off all 20/20 lab tests for life. (Only if available in your country)

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

PREVIOUSLY CROWDFUNDED
$10,469,835.00
RAISED
$232,186.66
INVESTORS
159
MIN INVEST
$500.00
VALUATION CAP
$58.4M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.